BioSpace News Archive

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organization effective January 29, 2021 to assume the role of chief executive officer at another healthcare company.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it is offering to sell shares of its common stock and pre-funded warrants, together with accompanying warrants to purchase shares of its common stock in an underwritten public offering.

Nation’s Largest Dental Support Organization Expands Footprint Adding Three Supported Regional Dental Groups, Single Offices, and New Builds.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Sachin H. Jain, MD, MBA.

Meitheal Pharmaceuticals, Inc. (“Meitheal”), announced today that it is voluntarily recalling one (1) lot of Cisatracurium Besylate Injection, USP 10mg per 5mL to the user level.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that the Company has begun enrolling patients into the expansion cohort portion of the ongoing Phase 1 clinical trial for ZW49, its novel HER2-targeted antibody-drug conjugate (ADC).

MJ Biotech, Inc. (MJTV), is pleased to announce, its wholly-owned Subsidiary, New England Biotech’s partner Genesis Botanical, signed its first contract with a Maine farmer to provide 40 acres of hemp biomass for extraction for the 2021 farming season.

Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen - Trial will evaluate the efficacy and safety of Pfizer’s targeted therapies, VIZIMPRO ® and XALKORI ® , in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test

The healthcare revenue cycle management market is likely to register significant gains in coming years owing to surging healthcare expenditure across the globe.

Demand for cloud computing applications in healthcare facilities like laboratories and hospitals to monitor patient-specific health information will expand the healthcare cloud computing market forecast over the coming years.